https://www.thebodypro.com/category/fda-approved-hiv-medications/tag/conference-coverage
FDA-Approved HIV Medications

Conference Coverage

The Latest

hand showing 2

As Two-Drug HIV Treatment Rises, Long-Term Inflammation Becomes a Potential Concern

These studies presented at AIDS 2020 explore the benefits and challenges.

By Myles Helfand
pregnant belly

Tempering Previous Concerns, Study Finds Dolutegravir Safest HIV Treatment During Pregnancy

New data shows the drug is not more likely to cause birth defects.

By Sony Salzman
pregnant woman talking to doctor

Raltegravir Not Linked to Birth Defects, Study Shows

Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.

By Kenyon Farrow
Pair of female feet on a bathroom scale

One Class of HIV Drugs Is Associated With Weight Gain. What's the Latest?

The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.

By Sony Salzman
Conference Centre at 10th IAS Conference on HIV Science (IAS 2019), Mexico City, Mexico

Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results

Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.

By Terri Wilder, M.S.W.
Christoph D. Spinner

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

By Sony Salzman
Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

By Sony Salzman
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo)

Fixed-Dose Doravirine Combination Non-Inferior in Treatment-Experienced Patients

Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...

By Barbara Jungwirth
Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring Img

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring

Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.

By Polly Clayden for HIV i-Base
Promo Image

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

By Mark Mascolini